Morphine/codeine ratio, a key in investigating a case of doping by Seif-Barghi, T. et al.
Asian J Sports Med. 2015 December; 6(4): e28798. doi: 10.5812/asjsm.28798
Published online 2015 December 1. Case Report
Morphine/Codeine Ratio, a Key in Investigating a Case of Doping
Tohid Seif-Barghi,
1,2
 Navid Moghadam,
2,3,*
 and Farzad Kobarfard
4
1Sports Medicine Research Center, Tehran University of Medical Sciences, Tehran, IR Iran
2Iran Football Medical Assessment and Rehabilitation Center (IFMARC), Tehran, IR Iran
3Sports Medicine Department, Rasool Akram Hospital, Iran University of Medical Sciences, Tehran, IR Iran
4Department of Medicinal Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran*Corresponding author: Navid Moghadam, Sports Medicine Department, Rasool Akram Hospital, Iran University of Medical Sciences, Tehran, IR Iran. Tel: +98-9352542280, 
E-mail: moghaddam.n@tak.iums.ac.ir
 Received 2015 March 18; Revised 2015 June 28; Accepted 2015 July 3
Abstract
Introduction: Consumption of codeine can lead to positive urine test for morphine in athletes. Morphine is classified as a prohibited 
doping drug while Codeine is not. Morphine/codeine ratio is used in forensic medicine to distinguish the consumption of codeine from 
abuse of morphine and other narcotics.
Case Presentation: We present an athlete with positive urine test for morphine with a history of consumption of codeine. The disciplinary 
committee came to conclusion that the athlete had not consumed morphine and did not violate doping code based on morphine/codeine 
ratio.
Conclusions: Analysis of codeine to morphine metabolism rate is needed when we are using morphine/codeine ratio to rule out abuse 
of narcotics. WADA should consider analysis for the CYP2D6 alleles (main metabolizer of codeine) in case of including morphine/codeine 
ratio in future prohibited list. The possibility of ultra-rapid CYP2D6 cannot be ruled out in certain results of morphine/codeine near the 
cut point.
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1. Introduction
Codeine or 3-methylmorphine (a natural methylated 
form of morphine) is widely used to manage mild to 
moderate pain and to relieve mild cough. Codeine is the 
most commonly used opiate in the world with a wide 
safety margin. Codeine is found in combination prepa-
rations with acetaminophen, aspirin or ibuprofen in 
many over-the-counter drugs used for cold symptoms 
and analgesia. These over-the-counter drugs are widely 
used by athletes for a wide range of conditions such as 
sport injuries to common cold. Codeine is not classified 
as prohibited drug by world anti-doping agency (WADA) 
but morphine (along some other narcotics) is one of the 
possible metabolites of codeine that is prohibited in the 
time of competition. Codeine is distinguished from mor-
phine by the methylation of hydroxyl group on C3 of the 
aromatic ring. Codeine mainly metabolizes to codeine-
6-glucuronide (C6G) by uridine diphosphate glucurono-
syl transferase (UGT2B7); but codeine can also undergo 
metabolism to morphine in the liver via cytochrome 
P450 2D6 (CYP2D6). Patients who took codeine have 
shown both codeine and morphine in their plasma and 
urine (1). Determining the origin of morphine found in a 
doping control urine sample of athletes can be challeng-
ing. The disciplinary committee of doping rules based on 
whether the finding is due to ingesting codeine or mor-
phine by the athlete. Intake of morphine can violate dop-
ing control code, but consumption of codeine is allowed 
due to the WADA current code.
Morphine/codeine (Mor/Cod) ratio is widely used in 
forensic medicine to differentiate between consuming 
codeine and morphine (2, 3). Mor/Cod ratio below 1 is 
considered as a sign of codeine only intake, whereas the 
ratio above 1 is considered as a sign of using morphine 
or heroin (4, 5). but the number of one is not absolute to 
determine the source of morphine, some suggested that 
in individuals with ultra-rapid CYP2D6 metabolism, Mor/
Cod ratio can be higher than 1 in even sole consumption 
of codeine.
Importance of this case report lies in the presence of 
Mor/Cod ratio in WADA 2015 monitoring program. This 
report can help WADA decide about its policy for dop-
ing control regarding narcotics. We have searched the 
PubMed database until February 2015 using key words: 
Morphine, Codeine, and Opioid Metabolism
2. Case Presentation
The doping case regarded the result of urine sample 
analysis of a 25-year-old male Futsal Premier League 
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player in season 2014 - 2015, Iran. He had no history of 
anti-doping rules violation. He was selected randomly 
for sampling during a match, mid-2014. His sample was 
positive for morphine, and was alleged to violation of 
article 6 of FIFA anti-doping regulations. FIFA anti- dop-
ing regulations refer to the WADA prohibited list to de-
fine prohibited drugs. The player denied using narcotics 
including morphine in testimony but admitted that he 
had taken a number of acetaminophen-codeine tablets 
( 300 mg and 10 mg, respectively), the day before match 
for controlling tooth pain. He did not remember the ex-
act number or the exact time of ingesting the tablets. The 
reported concentrations of morphine and codeine is his 
urine sample were 54.5 µg/ml and 52.7 µg/ml respectively. 
Mor/Cod ratio was 1.03 in this case, this Mor/Cod ratio was 
in agreement of Mor/Cod ratio reported by He et al. (6) 24 
hours after codeine consumption. Considering the fact 
that codeine is not among the WADA 2015 prohibited list, 
the positive result for morphine in urine sample was at-
tributed to codeine consumption.
He presented no significant past medical history, specif-
ically hepatic disease. The football player denied taking 
any drugs or substances but the acetaminophen-codeine 
tablets in the 2 months before testing.
The disciplinary committee came to the conclusion that 
the player had not violated anti-doping rules. The player 
could establish how the prohibited substance entered 
his system and had no intention for enhancing perfor-
mance. Therefore, according to article 21 of FIFA anti-dop-
ing regulations the doping case was dismissed.
3. Discussion
The disciplinary committee’s conclusion was based on 
assumption that the athlete can be an individual with 
ultra-rapid CYP2D6 metabolism. A study by He et al. (6) 
has shown that in the individuals with ultra-rapid CYP2D6 
metabolism, Mor/Cod ratios were below 1, median (range): 
0.108 (0.045 - 0.236) in plasma, 12 hours after codeine con-
sumption. But it could be above 1, median (range): 0.635 
(0.184 - 1.060) after 24 hours. UGT2B7 isozyme conjugates 
codeine and morphine to their corresponding 3- and 6- 
glucuronides. He et al. (6) also measured morphine 3-gluc-
uronide (M3G), morphine 6-glucuronide (M6G), codeine-
6-glucuronide (C6G) as forms other than free morphine 
and free codeine. (Mor + M3G + M6G)/ (Cod + C6G) ratio 
also have shown comparable results to (Mor/Cod) ratio. 
Another study by Kirchheiner et al. (7), using inverse ratio 
(Cod + C6G/ Mor + M3G + M6G) in plasma and urine sam-
ples has reported the inverse ratio to be 9 (6 - 16) in ultra-
fast metabolizers 12 hours after codeine consumption. 
CYP2D6 (cytochrome P450, family 2, subfamily D, poly-
peptide 6 ) is a member of the cytochrome P450 oxidase 
system, CYP2D6 is one of the enzymes which is involved 
in the metabolism of foreign chemical substance or sub-
stances presented with higher than normal concentra-
tions in the body as well as morphine. CYP2D6 accounts for 
small fraction of hepatic CYPs (< 2%) but metabolizes and 
eliminates about 25% of drugs which are used in clinic (8).
Some drugs like rifampicin and dexamethasone can 
increase the CYP2D6 metabolism through induction of 
CYP450 isozymes. Some other drugs like selective sero-
tonin reuptake inhibitors (SSRIs), paroxetine and fluox-
etine and the antidepressant, bupropion, and the class I 
antiarrhythmic agent, quinidine are CYP2D6 inhibitors 
and can reduce or even completely block the CYP2D6 me-
tabolism. People with multiple copies of the 2D6 gene 
also produce more CYP2D6 and will metabolize drugs 
faster than others. There is considerable evidence on as-
sociation between CYP2D6 genotype and variability in co-
deine metabolism to morphine. CYP2D6 metabolism in a 
subject can be described as poor metabolizer (with little 
or no metabolism), intermediate metabolizers (with a 
metabolism rate between poor and extensive), extensive 
metabolizer (with normal metabolism) or ultra-rapid 
metabolizer (with greater than normal metabolism due 
to multiple copies of CYP2D6 gene). The possible genomic 
or environmental mechanisms leading to the substantial 
difference among subjects with the same metabolizer 
group are unknown. Fatal intoxication, such as respira-
tory depression demanding airway intubation, can devel-
op in days after consumption of codeine in subjects with 
multiple functional alleles of CYP2D6 (ultra-rapid metab-
olism). Poor CYP2D6 metabolizers present lower analge-
sia after consumption of codeine. Clinical Pharmacoge-
nomics Implementation Consortium (CPIC) guidelines 
recommend against administration of codeine to ultra-
rapid CYP2D6 metabolizers because of higher risk of ad-
verse drug reactions due to morphine intoxication. And 
it is also recommended to use an alternative analgesic 
other codeine in poor CYP2D6 metabolizers because it is 
widely assumed that morphine is an active metabolite of 
codeine which is responsible for its analgesic effects (9).
In a clinical setting, a subject with CYP2D6 phenotype is 
usually determined by the administration of a selective 
CYP2D6 substrate (e.g. debrisoquine) and then measure-
ment of  plasma concentration of that substrate metab-
olite (4-hydroxydebrisoquine in case of using debriso-
quine) (10). Debrisoquine hydroxylation phenotype has 
been the most used test in humans to evaluate CYP2D6 
activity. Two CYP2D6 activity phenotypes have been de-
scribed using debrisoquine hydroxylation: poor and ex-
tensive metabolizers. Ultra-rapid metabolizers have very 
low debrisoquine metabolic ratio among the extensive 
metabolizer subjects.
CYP2D6 variability can be otherwise determined by ge-
notyping, because the CYP2D6 allele is the genetic basis 
of variability of CYP2D6 metabolism. Cytochrome P450 
Nomenclature Committee have defined More than 100 
CYP2D6 alleles. Subjects with certain alleles show different 
levels of CYP2D6 enzyme activity. Pharmacogenomic test-
ing can be used to determine the CYP2D6 allele of a subject 
(11). CYP2D6 pharmacogenetics can grow into a valuable 
instrument to predict drug side effects, interactions or 
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metabolisms. Nevertheless, for some reason, research in 
this field failed to bloom. A lot of CYP2D6 allele phenotypes 
have only been predicted based on their genetic variations 
or based on in vitro studies instead of clinical trials. Geno-
type test may also fail to cover rare CYP2D6 variants. Sub-
jects with rare CYP2D6 variants may be labelled as having 
“wild type” as default which can have different properties 
than that certain rare CYP2D6 variant.
Ethnicity is a factor in CYP2D6 variable function. There 
is a difference in the prevalence of different CYP2D6 al-
leles among different populations. Northern African and 
middle eastern populations show higher prevalence of 
ultra-rapid CYP2D6 metabolizers (12), the same ethnicity 
that the aforementioned player possessed.
The disciplinary committee was unable to conduct clin-
ical or genetic testing to determine CYP450 metabolism 
due to some limitations. The committee ruled that no 
violation of doping code occurred with presumption of 
innocence as a law principle. The committee was unable 
to determine the metabolism rate CYP2D6 of the given 
athlete; and considering the possibility of ultra-rapid 
CYP2D6 metabolism in the athlete, the committee had no 
satisfactory evidence of violation of doping code.
Morphine/codeine ratio is used along with a number of 
narcotics (Hydrocodone, mitragynine, tapentadol and 
tramadol) in WADA 2015 monitoring program. WADA 
monitoring program aims to detect misuse patterns 
among sportspersons. As we mentioned, interpreta-
tion of morphine/codeine depends on determination of 
CYP2D6 metabolism. We could not exclude the possibil-
ity of ultra-rapid CYP2D6 metabolism in case of our spe-
cific athlete because of near the cut point result of mor-
phine/codeine ratio. In athletes with results close to the 
cut point of morphine/codeine ratio we cannot rely on 
the results because of possibility of ultra-rapid CYP2D6 
metabolism. If WADA is going to include morphine/co-
deine ratios above 1 (the cut point) in prohibited list, they 
should consider that this number can vary in certain ath-
letes with ultra-rapid CYP2D6 metabolism. We suggest 
that WADA consider that clinical and/or pharmacoge-
nomic testing for CYP2D6 metabolism is needed in case 
that WADA is planning to use Morphine/Codeine ratio 
in investigation for violation of doping code. Including 
Morphine/Codeine ratio without considering varied CY-
P2D6 metabolism can lead to legal difficulties in future 
cases of doping. Polymerase chain reaction tests (PCR) 
analyze the alleles of CYP2D6 (7) to determine the geno-
type; the genotype corresponds to a score in a semi quan-
titative gene-dose system that gives a number to each 
consisting allele of genotype (13). The result of that scor-
ing system shows the metabolism rate of CYP2D6 system. 
Aforementioned Problems in pharmacogenomic testing 
(lack of clinical data on some alleles and problems in de-
tecting rare alleles) and side effect of drugs on CYP2D6 
metabolism should also be considered in future deci-
sions regarding using morphine/codeine ratio in doping 
control by WADA.
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